# Temozolomide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Anaplastic Oligodendrogliomas or Mixed Anaplastic Oligoastrocytomas

> **NCT00033280** · PHASE2 · COMPLETED · sponsor: **Radiation Therapy Oncology Group** · enrollment: 42 (actual)

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **DRUG:** temozolomide
- **PROCEDURE:** neoadjuvant therapy
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00033280
- **Lead sponsor:** Radiation Therapy Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-07
- **Primary completion:** 2005-04
- **Final completion:** 2018-05-14
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2020-10-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00033280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00033280, "Temozolomide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Anaplastic Oligodendrogliomas or Mixed Anaplastic Oligoastrocytomas". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00033280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*